Schlack Katrin
Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland.
Urologie. 2023 Apr;62(4):407-417. doi: 10.1007/s00120-023-02061-0. Epub 2023 Mar 1.
In 2020 the number of cases of newly diagnosed urothelial cancer in Germany was approximately 35,000, making urothelial cancer the fifth most common form of cancer in this country in terms of incidence. If systemic recurrence occurs the risk of dying from urothelial cancer is high. For this reason, perioperative concepts that improve the overall survival around curatively intended cystectomy are becoming increasingly more important as part of multimodal concepts for urothelial cancer. In the neoadjuvant setting, platinum-based chemotherapy currently remains the gold standard and can also be used in the adjuvant setting. Recently, immunotherapy has gained in importance for adjuvant treatment. Further innovations, such as the use of immunotherapy in the neoadjuvant setting or combination therapies in both situations can be expected. This article provides insights into the current recommendations and highlights possible new concepts.
2020年，德国新诊断出的尿路上皮癌病例数约为35000例，就发病率而言，尿路上皮癌是该国第五大常见癌症形式。如果发生全身复发，死于尿路上皮癌的风险很高。因此，作为尿路上皮癌多模式治疗理念的一部分，改善根治性膀胱切除术周围总体生存率的围手术期治疗理念变得越来越重要。在新辅助治疗中，铂类化疗目前仍是金标准，也可用于辅助治疗。最近，免疫疗法在辅助治疗中的重要性日益凸显。预计会有进一步的创新，例如在新辅助治疗中使用免疫疗法或在两种情况下都采用联合疗法。本文深入探讨了当前的建议，并重点介绍了可能的新概念。
